抗逆转录病毒治疗时机与出生体重对母婴人类免疫缺陷病毒传播的影响:津巴布韦从方案A向方案B+过渡期间全国代表性母婴配对18个月前瞻性队列研究结果
该研究在津巴布韦从方案A向方案B+过渡期间,采用多阶段分层整群抽样连续纳入151家免疫接种门诊的6051名4-12周龄婴儿及其母亲,其中1172名HIV暴露婴儿随访至18月龄。结果显示18个月累计母婴传播风险为7.0%;与未使用抗逆转录病毒药物的母亲相比,孕前启动ART和孕期启动ART分别使传播风险降低88%(aHR 0.12,95%CI 0.06-0.24)和75%(aHR 0.25,95%CI 0.14-0.45);出生体重<2.5 kg的HIV暴露婴儿感染风险为出生体重≥2.5 kg者的2.57倍(aHR 2.57,95%CI 1.44-4.59)。
要点
- 孕前启动ART对减少母婴传播影响最大,HIV感染育龄妇女应在「全员治疗」策略中优先。
- 未使用ART的HIV感染母亲应在首次免疫接种访视时被识别并启动治疗以减少产后传播。
- 低出生体重分娩母亲的母婴传播风险更高(aHR 2.57,95%CI 1.44-4.59)。
核心结论
- 孕前启动ART对减少母婴传播影响最大,表明HIV感染育龄妇女应在「全员治疗」策略中优先。
- 未使用ART的HIV感染母亲应在首次免疫接种访视时被识别并启动治疗以减少产后母婴传播。
- 低出生体重分娩母亲的母婴传播风险更高。
研究设计与样本
- 2013年采用多阶段分层整群抽样方法,从151家免疫接种门诊连续招募全国代表性样本6051名4-12周龄婴儿及其母亲。
- 识别1172名HIV暴露婴儿,在基线及每3个月评估一次,直至婴儿感染HIV、死亡或达到18月龄。
主要发现
- 产后18个月累计母婴传播风险为7.0%。
- HIV感染母亲中35.3%孕前启动ART,28.9%孕期启动,9.7%产后启动,16.0%孕期接受齐多夫定。
- 与未使用抗逆转录病毒药物的母亲相比,孕前启动ART者母婴传播降低88%(aHR 0.12,95%CI 0.06-0.24),孕期启动者降低75%(aHR 0.25,95%CI 0.14-0.45)。
- 出生体重<2.5 kg的HIV暴露婴儿感染风险为出生体重≥2.5 kg者的2.57倍(aHR 2.57,95%CI 1.44-4.59)。
- 控制其他因素后,母乳喂养与母婴传播无显著关联。
临床怎么用
- HIV感染育龄妇女应在「全员治疗」策略中优先(作者结论)。
- 未使用ART的HIV感染母亲应在首次免疫接种访视时被识别并启动治疗以减少产后传播(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preventing mother-to-child transmission of human immunodeficiency virus transmission (MTCT) depends on early initiation of antiretroviral therapy (ART). We report the 18-month MTCT risk during the transition from Option A to Option B+ in Zimbabwe, and assess whether ART preconception could eliminate MTCT in breastfeeding populations. METHODS: In 2013, we consecutively recruited a nationally representative sample of 6051 infants aged 4-12 weeks and their mothers from 151 immunization clinics using a multistage stratified cluster sampling method. We identified 1172 human immunodeficiency virus (HIV)-exposed infants and evaluated them at baseline and every 3 months until the child became HIV-infected, died, or reached age 18 months. RESULTS: The cumulative MTCT risk through 18 months postdelivery was 7.0%. Of the HIV-infected mothers, 35.3% started ART preconception, 28.9% during pregnancy, and 9.7% after delivery, and 16.0% received zidovudine during pregnancy. Compared to mothers without antiretroviral drug use, MTCT among those starting ART preconception and during pregnancy was lower by 88% (adjusted hazard ratio [aHR], 0.12; 95% confidence interval [CI], .06-.24) and 75% (aHR, 0.25; 95% CI, .14-.45), respectively. HIV-exposed infants with birth weight <2.5 kg (low birth weight) were 2.6-fold more likely to acquire HIV infection compared to those with birth weight ≥2.5 kg (aHR, 2.57; 95% CI, 1.44-4.59). Controlling for other factors, breastfeeding was not significantly associated with MTCT. CONCLUSIONS: ART preconception has the highest impact on reducing MTCT, indicating that HIV-infected, reproductive-age women should be prioritized in "treat-all" strategies. HIV-infected mothers without ART use should be identified at the first immunization visit and treatment initiated to reduce postdelivery MTCT. MTCT risk is higher in mothers with low-birth-weight deliveries.
引用
- Dinh TH, Mushavi A, Shiraishi RW, et al. Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother-Infant Pairs During the Transition From Option A to Option B+ in Zimbabwe. Clin Infect Dis. 2018. PMID: 29401270. doi:10.1093/cid/cix820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。